Lesson focus: Histamine H₂-receptor antagonists (H₂ blockers/H₂RAs) reduce gastric acid secretion. They remain useful for selected dyspepsia, reflux and ulcer-related situations, but they are not interchangeable with proton-pump inhibitors (PPIs), do not eradicate Helicobacter pylori, and must not delay assessment of gastrointestinal bleeding or cancer warning signs.
Learning objectives
By the end of this lesson, the learner should be able to explain histamine’s role in acid secretion; distinguish H₁, H₂, H₃ and H₄ receptors; classify H₂ blockers; compare cimetidine, famotidine, nizatidine and ranitidine; select appropriate clinical uses; recognise when an H₂ blocker is insufficient; prevent important interactions and adverse effects; and counsel a patient safely.
1. Core foundation: histamine and the gastric parietal cell
Histamine is an endogenous autacoid and neurotransmitter formed by decarboxylation of the amino acid histidine. It is stored especially in mast cells and basophils, and is present in the skin, respiratory and gastrointestinal mucosa, brain and other tissues. Its actions depend on receptor subtype; therefore an “antihistamine” is not one single clinical group.
| Receptor | Main sites | Key effects | Clinical link |
|---|---|---|---|
| H₁ | Endothelium, smooth muscle, sensory nerves, CNS | Itching, increased vascular permeability, bronchoconstriction, allergic symptoms | Blocked by H₁ antihistamines for allergy/urticaria |
| H₂ | Gastric parietal cells; also heart, vascular and immune cells | Stimulates gastric acid secretion | Blocked by H₂ blockers for acid reduction |
| H₃ | Presynaptic CNS and peripheral nerves | Modulates histamine and other neurotransmitter release | Not a peptic-ulcer drug target |
| H₄ | Bone marrow and immune cells | Immune-cell chemotaxis and inflammation | Not a routine GI-drug target |
How acid is produced
Three principal stimulants act synergistically on the gastric parietal cell: acetylcholine from vagal nerves at M₃ receptors, gastrin at CCK-B receptors, and histamine released by enterochromaffin-like (ECL) cells at H₂ receptors. H₂ activation couples through Gs to adenylate cyclase, raises intracellular cAMP and activates protein kinase A. This increases activity of the final common pathway, the apical H⁺/K⁺-ATPase (proton pump), which secretes H⁺ into the stomach lumen.
Why H₂ blockade works: blocking histamine at the parietal-cell H₂ receptor reduces cAMP-mediated acid secretion and also weakens the potentiating effect that histamine normally has on acetylcholine and gastrin. It is therefore an indirect reduction of proton-pump output. PPIs inhibit the pump itself and usually suppress acid more profoundly.
2. What are H₂-receptor antagonists?
H₂ blockers are reversible, competitive antagonists at parietal-cell H₂ receptors. They reduce basal and stimulated gastric acid secretion, particularly basal and nocturnal acid output. They also reduce pepsin secretion secondarily because pepsin activity depends on an acidic environment.
Cimetidine
Prototype H₂ blocker. Most interaction-prone and most endocrine adverse effects.
Famotidine
Common modern choice where available; little CYP inhibition but adjust in renal impairment.
Nizatidine
H₂ blocker with few CYP interactions; availability varies.
Ranitidine
Historical drug. Do not assume it is available or appropriate: many markets withdrew products because of NDMA impurity concerns.
Important correction to a common phrase
H₂ blockers are sometimes loosely called “antihistamines,” but in peptic-ulcer practice they are acid-suppressing H₂ antagonists, not H₁ allergy medicines. An H₁ blocker such as chlorpheniramine does not treat a peptic ulcer by blocking parietal-cell H₂ receptors.
3. Pharmacodynamics: what H₂ blockers can and cannot do
- They lower gastric volume and hydrogen-ion concentration, raise intragastric pH and promote healing of many uncomplicated acid-related ulcers.
- They are especially useful when symptoms are nocturnal or intermittent because histamine has a prominent role in nocturnal acid secretion.
- They are less potent than PPIs for severe erosive oesophagitis, high-risk upper-GI bleeding and strong continuous acid suppression.
- Tolerance (tachyphylaxis) may develop with regular continuous use, often after days to weeks. This makes persistent daily symptoms a reason to reassess the diagnosis and treatment plan rather than simply escalating indefinitely.
- They give symptomatic acid relief; they do not eradicate H. pylori, replace endoscopic haemostasis in bleeding ulcer, or remove the ulcerogenic effect of ongoing NSAID exposure.
4. Medicinal-chemistry/SAR principles from the supplied lecture
The H₂ antagonists were developed by modifying histamine to preserve receptor recognition while converting agonist activity into competitive antagonism. The imidazole ring is not mandatory: heterocyclic rings such as furan, thiophene and thiazole can support H₂-receptor selectivity and potency. A flexible side chain separates the heterocyclic ring from a polar, relatively non-basic terminal group. The lecture emphasises an approximately four-atom separation between ring and terminal nitrogen and notes thioether/isosteric linkages in several molecules.
5. Individual drugs: compare before you prescribe
| Drug | Key characteristics | Major cautions | Practical place |
|---|---|---|---|
| Cimetidine | Oldest prototype; inhibits several CYP enzymes and can increase concentrations of interacting medicines | Gynecomastia, sexual dysfunction, galactorrhoea, confusion in older/renal-impaired patients, many interactions | Usually avoided when a lower-interaction H₂ blocker is available |
| Famotidine | Potent; minimal CYP inhibition | Reduce dose/extend interval in renal impairment; CNS effects and QT-risk concern are greater when drug accumulates | Often preferred H₂ blocker for intermittent/nocturnal symptoms |
| Nizatidine | Few CYP interactions; availability varies | Renal elimination: dose-adjust in renal impairment; check local formulary | Alternative where stocked |
| Ranitidine | Previously widely used, fewer interactions than cimetidine | NDMA-related market withdrawal/restrictions in many jurisdictions; never prescribe from outdated notes without checking national regulatory status | Historical/exam knowledge only unless confirmed locally authorised |
5.1 Cimetidine: the interaction and endocrine drug
Cimetidine competitively blocks H₂ receptors but also inhibits hepatic microsomal drug metabolism, notably CYP-mediated pathways. It can raise levels of medicines with narrow therapeutic windows or dose-related toxicity. Always obtain a complete medication history, including warfarin, phenytoin, theophylline, some antiarrhythmics and other locally used medicines. The exact interaction depends on the co-medicine; check an interaction reference rather than memorising an incomplete list.
- Endocrine/antiandrogenic effects: gynecomastia, reduced libido, erectile dysfunction and occasionally galactorrhoea, particularly with high dose or prolonged use.
- CNS effects: confusion, agitation or delirium are more likely in frail older adults or renal impairment.
- Prescribing principle: cimetidine is rarely the first choice where famotidine is available, especially in polypharmacy.
5.2 Famotidine: low interaction burden, not low-risk in renal failure
Famotidine has little clinically important CYP inhibition, which is a major practical advantage. However, it is substantially renally cleared. In moderate-to-severe renal impairment, accumulation increases the risk of CNS adverse reactions such as confusion, delirium, hallucinations, lethargy or seizures; dose reduction or interval extension is required. The current prescription label also warns about QT prolongation risk in renal impairment.
Do not copy a standard adult dose into a prescription without checking renal function. Use the local formulary/label for the indication-specific dose and renal adjustment. Dose schedules vary by ulcer, reflux, hypersecretory state, age and route.
5.3 Nizatidine
Nizatidine is an H₂ blocker with a lower enzyme-interaction burden than cimetidine. It still requires renal-dose consideration and may not be routinely available. A learner should distinguish pharmacological class knowledge from local stock: prescribing must follow the facility formulary and verified product information.
5.4 Ranitidine: historical knowledge and drug-safety literacy
Ranitidine appears in many older lectures, formularies and examination questions. In 2020 the US FDA requested removal of ranitidine products from its market after finding that NDMA, a probable human carcinogen, could increase during storage, especially at higher temperatures. Regulatory status is country-specific and can change. For real prescribing, check the current national medicines authority/formulary; do not advise a patient to restart old ranitidine tablets stored at home.
6. Clinical uses
6.1 Intermittent heartburn, dyspepsia and reflux symptoms
H₂ blockers may be used for selected mild or intermittent acid-related symptoms, including nocturnal heartburn. For ongoing or recurrent gastro-oesophageal reflux disease (GORD), PPIs generally give stronger healing and symptom control, particularly for erosive disease. NICE guidance allows an H₂ blocker when response to a PPI is inadequate and supports using the lowest effective dose for recurring symptoms after initial management.
6.2 Peptic ulcer disease
H₂ blockers can heal uncomplicated gastric or duodenal ulcers by lowering acid exposure. But every ulcer requires a cause-based plan:
- H. pylori-associated ulcer: test appropriately and give a guideline-based eradication regimen; acid suppression alone is incomplete treatment.
- NSAID-associated ulcer: stop/reduce the NSAID if possible, assess the indication and gastroprotection, test/treat H. pylori when appropriate, and use a PPI when stronger healing/prevention is indicated.
- Complicated or bleeding ulcer: resuscitation, urgent referral/endoscopy and guideline-based high-dose acid suppression are required. An outpatient H₂ blocker is not definitive care.
6.3 Prevention of stress-related mucosal injury
In selected critically ill patients at significant risk of stress-related upper-GI bleeding, acid suppression may be used according to the institution’s protocol. Do not prescribe stress-ulcer prophylaxis to every hospitalised patient automatically: balance risk, route, interactions, infection risk and the need to stop prophylaxis when the high-risk period ends.
6.4 Pathological hypersecretory states
H₂ blockers can suppress acid in hypersecretory states such as Zollinger–Ellison syndrome, but such cases require specialist-directed diagnosis and high-dose, monitored therapy. PPIs are frequently preferred in contemporary practice because they are more potent.
7. When an H₂ blocker is not enough: triage and red flags
Urgent assessment/referral is needed for haematemesis, coffee-ground vomit, melaena, syncope, shock, severe persistent epigastric pain, suspected perforation, progressive dysphagia, persistent vomiting, unintentional weight loss, iron-deficiency anaemia, a palpable mass, or symptoms suggesting cancer. Do not mask these with repeated over-the-counter acid suppression.
For dyspepsia that persists, worsens, recurs frequently or fails appropriate treatment, review adherence, pregnancy status, NSAID/aspirin exposure, alcohol/tobacco use, alarm symptoms and H. pylori testing strategy. In adults with dyspepsia/reflux, guidance supports testing for H. pylori using validated breath or stool-antigen testing where available. A PPI should be stopped sufficiently before testing to avoid a false negative; follow the local protocol.
8. Adverse effects and monitoring
| Problem | What to look for | Action |
|---|---|---|
| Common, usually mild | Headache, dizziness, fatigue, constipation or diarrhoea, nausea, dry mouth, sleep disturbance | Assess severity; review need, duration and alternative cause |
| CNS toxicity | Confusion, agitation, delirium, hallucinations, lethargy—especially older adult or renal impairment | Stop/reduce; check renal function, interacting medicines and other causes; seek clinical review |
| Endocrine effects | Gynecomastia, reduced libido, erectile dysfunction, galactorrhoea | Think cimetidine; switch after clinical review |
| Cardiac risk | Palpitations/syncope, particularly with renal accumulation or QT-risk medicines | Review renal function and co-prescribed QT-prolonging drugs; urgent assessment if symptomatic |
| Masked diagnosis | Symptoms improve briefly but weight loss, bleeding or dysphagia develops | Do not continue empirical treatment; investigate/refer |
9. Interactions: two mechanisms to remember
A. Cimetidine changes drug metabolism
Cimetidine can inhibit CYP enzymes and thereby increase exposure to co-prescribed drugs. The safe method is not to rely on a short memorised list: identify all prescription, OTC and herbal products; check an interaction database/formulary; assess whether a different H₂ blocker or PPI is preferable; and arrange monitoring where a clinically important interaction is unavoidable.
B. All H₂ blockers can change pH-dependent absorption
By increasing gastric pH, H₂ blockers may reduce absorption of medicines that need an acidic stomach environment. Examples can include certain azole antifungals and some antiretrovirals; the effect and management are drug-specific. Separating doses does not solve every pH-dependent interaction—check the product information.
Medication-history question: “Are you taking ulcer/heartburn medicine?” must be asked before initiating a medicine with pH-dependent absorption, and “What other medicines—including warfarin, seizure medicines, asthma medicines and herbs—do you use?” should be asked before selecting cimetidine.
10. Special populations
Older adults
Use the lowest effective dose for the shortest appropriate time. Renal function commonly declines with age, so standard dosing can lead to accumulation and confusion. New delirium after an H₂ blocker is a medication safety signal.
Renal impairment
Assess creatinine clearance/eGFR and use the current formulary for dose adjustment. Famotidine and nizatidine need particular attention because of renal elimination. Do not interpret a “normal-looking” serum creatinine in a frail patient as proof of normal renal clearance.
Pregnancy and breastfeeding
Do not use a class mnemonic as a prescribing decision. Confirm the indication, try non-drug measures where appropriate, and consult current national/obstetric guidance and product information. Maternal alarm features always require assessment.
Children
Over-the-counter age restrictions in old teaching slides are not a complete paediatric rule. Weight-based dosing, diagnosis and duration require paediatric guidance; persistent vomiting, poor growth, GI bleeding or suspected ingestion needs review rather than self-treatment.
11. Counselling a patient
- Explain the purpose: “This reduces acid. It is not an antibiotic and it does not cure every cause of upper abdominal pain.”
- Take exactly as prescribed; night dosing may be selected when nocturnal symptoms are the target.
- Do not extend self-treatment repeatedly without review, especially if symptoms recur or need daily medicine.
- Bring all medicines to review; avoid starting cimetidine without interaction assessment.
- Seek urgent care for black stools, vomiting blood, fainting, severe worsening pain, difficulty swallowing, persistent vomiting or unexplained weight loss.
- Avoid continuing ulcer-causing NSAIDs without clinician advice. Ask specifically about ibuprofen, diclofenac, aspirin and traditional/herbal products.
12. H₂ blockers versus PPIs: exam and practice comparison
| Feature | H₂ blocker | PPI |
|---|---|---|
| Target | Histamine H₂ receptor on parietal cell | H⁺/K⁺-ATPase proton pump |
| Acid suppression | Moderate; especially nocturnal/basal acid | More potent and sustained |
| Tolerance with continuous use | Can develop | Not the typical limiting issue |
| Best-recognised roles | Intermittent/nocturnal heartburn; selected dyspepsia/reflux situations | Erosive GORD, stronger ulcer healing, guideline-based management of many high-risk acid conditions |
| Key safety trap | Cimetidine interactions/endocrine effects; renal accumulation | Indication, duration and interaction review still needed |
13. Clinical cases
Case 1: nocturnal heartburn
A 27-year-old has occasional burning retrosternal discomfort after late meals, mainly at night, with no dysphagia, bleeding, weight loss or persistent vomiting. An H₂ blocker may be reasonable for short, targeted symptom control after clinical assessment and lifestyle advice. Recurrent symptoms still need review; do not assume all chest burning is simple reflux.
Case 2: cimetidine in polypharmacy
A 68-year-old with renal impairment on multiple medicines asks for cimetidine for dyspepsia. The safe response is to review renal function and the full medication list, avoid a high-interaction choice if possible, and investigate persistent symptoms. A low-interaction alternative is not automatically safe without renal-dose adjustment.
Case 3: “ulcer” with black stool
A patient with epigastric pain after diclofenac reports melaena and dizziness. This is possible upper-GI bleeding: urgent assessment/resuscitation and referral are needed. Giving an oral H₂ blocker and sending the patient home is unsafe.
14. High-yield recall
- H₂ blockers are competitive H₂ antagonists on gastric parietal cells.
- They reduce basal and nocturnal acid secretion and weaken histamine’s amplification of gastrin/ACh effects.
- Famotidine: fewer CYP interactions; reduce dose in renal impairment.
- Cimetidine: CYP inhibition + gynecomastia/sexual adverse effects + interaction burden.
- Ranitidine: historical drug; verify current regulatory availability because of NDMA-related restrictions/withdrawal.
- Do not confuse acid suppression with ulcer-cause treatment: test/treat H. pylori, address NSAIDs, and refer complications.
- Alarm symptoms override empirical treatment.
Sources for further study
- Supplied lecture: H1 & H2 receptor antagonist (SlideShare).
- DailyMed: Famotidine prescribing information.
- NICE CG184: GORD and dyspepsia in adults: recommendations.
- American College of Gastroenterology: H. pylori guidance.
- US FDA: Ranitidine market withdrawal notice.
